Anavar
Brand name for oxandrolone, a synthetic DHT-derived anabolic steroid; historically used at 10 mg sublingually to displace testosterone from SHBG, freeing up bioavailable testosterone
As defined in Testosterone & Testosterone Replacement Therapy (TRT) | Dr. Peter Attia & Dr. Andrew Huberman
Where it comes up · 1
- Testosterone & Testosterone Replacement Therapy (TRT) | Dr. Peter Attia & Dr. Andrew Huberman5 claims
Most important claims · 5 of 5Search all claims for “Anavar” →
- Anavar (oxandrolone) is a DHT-derived anabolic steroid with high affinity for SHBG, and microdoses can increase free testosterone by displacing testosterone from SHBG without suppressing endogenous testosterone production if dosed small enoughTestosterone & Testosterone Replacement Therapy (TRT) | Dr. Peter Attia & Dr. Andrew Huberman
- Clomiphene is oral and intended for oral administration, with typical starting doses around 50 mg three times per week, making it more patient-friendly than Anavar's sublingual routeTestosterone & Testosterone Replacement Therapy (TRT) | Dr. Peter Attia & Dr. Andrew Huberman
- The physician no longer uses Anavar (oxandrolone) in clinical practice despite its theoretical utility for SHBG reduction, because it is too complex for patients to comply with (sublingual dosing) and carries risks of severe hepatotoxicity if taken incorrectlyTestosterone & Testosterone Replacement Therapy (TRT) | Dr. Peter Attia & Dr. Andrew Huberman
- Younger cohorts of men in their teens and twenties are increasingly seeking testosterone injections or anabolic steroids primarily for cosmetic effects rather than treating actual hypogonadismTestosterone & Testosterone Replacement Therapy (TRT) | Dr. Peter Attia & Dr. Andrew Huberman
- In current clinical practice (6–7 years before this conversation), physicians used microdoses of Anavar (oxandrolone) at 10 mg sublingually 2–3 times per week to lower SHBG in patients with normal total testosterone but low free testosteroneTestosterone & Testosterone Replacement Therapy (TRT) | Dr. Peter Attia & Dr. Andrew Huberman